There is a wide variability in the outcome of positivity of an anti-body in the serum of patients depending upon the techniques used. Therefore, the present study was undertaken to compare and critically analyzed the detection of anticytoskeletal autoantibodies by three different techniques in well defined patients of autoimmune diseases. Study included fifty well defined patients with rheumatoid arthritis and progressive systemicsclerosis. Fifty normal individuals were used as control. Cytoskeletal proteins-actin, myosin, tropomyosin were purified from chicken skeletal muscles. Tubulin purified from goat brain and spectrin was purified from human erythrocytes. Anticytoskeletal autoantibodies were detected by indirect immunoflourescence, immunoblotting and enzyme linked immunosorbent assay and results statistically analyzed and compared. By indirect immunoflourescence, RA exhibited 82% anti-myofibriller and 74% anti-cytoplasmic staining pattern where as PSS showed 48% and 50% staining pattern for respective proteins. Normals exhibited 6% antimyofibriller staining and 4% anticytoplasmic staining pattern. By ELISA in RA group antibody positivity exhibited for anti-actin, anti-myosin, anti-tubulin, anti-tropomyosin and anti-spectrin as for 11, 15, 9, 3 and 7 patients respectively. Compared to this in PSS group for respective proteins antibody positivity found as in 8, 7, 2, 1 and 0 patients. Out of 35 normal subjects anti-actin antibody was found in 2 volunteers while anti-myosin, anti-tubulin, anti-tropomyosin and antispectrin antibody was found in 1 normal control. The reactivity of sera to each of the 5 purified cytoskeletal antigens was negative by western blot (immunoblotting) for the patients with PSS and normal controls. Only 30% reactivity to myosin and 22% reactivity to tubulin by western blot was observed in RA group. Therefore, there is a difference in the prevalence of anticytoskeletal anti-body in each group when different techniques are used for detection. Evidently wide variability in the outcome of positivity of an antibody is observed depending upon the techniques used. Thus, depending upon the specific needs, researchers have to decide which method to adopt.
There is an individual behind every sample tested in a clinical lab, and that person's medical care depends on the correctness and quality of result. This central fact distinguishes clinical mass spectrometry from all other biomedical applications of mass spectrometry. Traditionally, various other technologies, including chromatography, immunoassays (RIA, CIA and ICMAs), have been used to supply the physician with analytical information needed for patient care. However, large reference laboratories and medical centers have shown that mass spectrometry often provides better quality testing and improved patient care. Besides great success, clinical mass spectrometry provides its own unique challenges opportunities, both to the mass spectrometrist and to the clinical chemist. This lecture will focus on mass spectrometry as practiced in the clinical world, including such diverse topics as current technologies and applications, emerging technologies and applications, validation and quality issues, medical issues, and other topics.
Recognition that catecholamines are metabolized to free metanephrines within pheochromocytoma tumor cells, and that this process is independent of catecholamine release, provides a rationale for use of these metabolites in the diagnosis of pheochromocytoma. The diagnostic superiority of metanephrines over catecholamines has led to the recommendation that initial testing for pheochromocytoma should always include measurements of metanephrines in plasma or urine or both. Consequently, the development of new and improved methods to measure plasma free metanephrines has received considerable attention. The recognition of the fact that Vitamin D deficiency may be more prevalent in most patient populations than earlier assumed has resulted in unexpected increase in the testing volume of 25-OH-Vit-D for the clinical laboratories. Historically, there have not been many diseases or tests in the clinical laboratories for which the number of patients being tested would have increased at the rate of 80-90% per year which is definitely the case for testing of 25-OH-Vit-D in our reference laboratory. It is anticipated that more than few million 25-OH-Vit-D tests will be performed alone this year in the US by various reference and local hospital laboratories. The traditional RIA methodology used for testing has been replaced with tandem mass spec technology. Evidence based medicine has been described as the conscientious explicit and judicious use of current best evidence in making decisions about the care of individual patients (Sackett et al, 1996) . Clinical assessment of the prostatic disease is often difficult due to small size and complex anatomy of the prostate and its inaccessible location deep within the pelvis. Traditionally, prostatic disease has been evaluated by digital rectal examination in combination with other clinical data like PSA, free PSA, biopsies for cancer (Wood P et al 2000) . Melia et al have analysed the use of PSA levels and its positive predictive value for cancer detection in men referred with a raised PSA in first degree related males. In 21 males referred in their study, five were diagnosed with prostate cancer (ppv = 24 %) amongst the first-degree related males. Many studies are available, commenting on the role of PSA in screening and early detection of prostate cancer (Catalona et al 1991 , Stamey et al 1993 However, the lack of greater specificity of total PSA testing has lead to increase in unnecessary biopsies hence another test of free to total PSA came into use .The use of F/T PSA ratio has extensively been studied (Thakur et al 2004) .Apart from this , the new noninvasive imaging technique such as TRUSP have been developed to aid in this evaluation (Kurhanewicz et al ,2000) . Clinical utility of MRI and MRSI in assessing PC has been well studied (Hricak H et al 1994 , Kalbhen C L 1996 . MRSI may provide an assessment of cancer aggression and can detect residual or recurrent cancer after therapy. These diagnostic procedures are also helpful in detecting early cancer.With these newer modalities there has been a shift towards the detection of early stage prostate cancers that are still confined to the prostate and potentially curable by currently available treatment modalities (Slawin et al 1995) . In large series of men treated with radical prostatectomy for clinically localized prostate cancer, more than 50 percent had evidence of disease progression outside the prostatic capsule at the time of surgery (Rosen et al 1992) ,such patients show high risk of biochemical progression .The patients treated with radiation therapy for clinically localized cancer show progression clinically as well as biochemically (Zagars et al 1994) .Hormonal therapy also temporarily controls the disease once it becomes disseminated. Standard chemotherapeutic agents have yielded disappointing results. New possibly more effective gene therapy is still on the distant horizon.
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